Showing 1811-1820 of 2320 results for "".
- New Bimekizumab Phase 3 Data Presented at EADVhttps://practicaldermatology.com/news/new-bimekizumab-phase-3-data-presented-at-eadv/2460594/UCB shared detailed results of the head-to-head Phase 3 BE SURE study, which demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved superior skin clearance, as compared to adalimumab, in adults with moderate to severe plaque psoriasis. These findi
- AbbVie Presents Additional Phase 3 Data for Upadacitinibhttps://practicaldermatology.com/news/abbvie-presents-additional-phase-3-data-on-upadacitinib/2460591/Significantly more patients treated with AbbVie’s upadacitinib in both of the Measure Up 1 and 2 studies
- EADV Congress Update: Insights on Psoriasis, AD, UV Protection, COVID-19, and Morehttps://practicaldermatology.com/news/eadv-congress-update-insights-on-psoriasis-ad-uv-protection-covid-19-and-more/2460588/From updates on investigational treatments for dermatologic diseases to emerging healthcare trends, data from the 29th EADV Congress, EADV Virtual suggest new directions in patient care. Psoriasis: Results from the phas
- Where is the Hydroquinone? Regulatory Change Hinders Accesshttps://practicaldermatology.com/news/where-is-the-hydroquinone-regulatory-change-hinders-access/2460586/Changes to FDA regulations implemented as part of the CARES Act this spring have left dermatologists and their patients scrambling to access hydroquinone. Although access is hindered, it is not cut off. “I think most people at this point are familiar with the CARES Act. What they
- Exclusive: Global Report Identifies Strategies for Improved Quality of Care in ADhttps://practicaldermatology.com/news/exclusive-global-report-identifies-strategies-for-improved-quality-of-care-in-ad/2460585/Gathering and synthesizing data from in-person visits from 32 care centers in 17 countries around the world, the “Improving Quality of Care in AD” report offers clear recommendations to improve care and help patients better manage atopic dermatitis.Commissioned and funded by Sano
- Sklice Goes Over-the-Counterhttps://practicaldermatology.com/news/sklice-goes-over-the-counter/2460581/Sklice (ivermectin) lotion, 0.5% is now approved for OTC sale. Sklice (Arbor Pharmaceuticals) was originally FDA approved as a prescription treatment for head lice infestation in patients six months of age and older in February 2012. “The Rx-t
- Arcutis: Phase 1/2b Enrollment Complete for ARQ-252 in Chronic Hand Eczemahttps://practicaldermatology.com/news/arcutis-phase-12b-enrollment-complete-for-arq-252-in-chronic-hand-eczema/2460578/Arcutis Biotherapeutics, Inc. has completed enrollment in the Phase 1/2b studyof its Janus kinase type 1(JAK1) ARQ-252 in adult patients with chronic hand eczema. Arcutis has updated its projected topline data from this trial to mid-2021.
- NRS Survey Reveals Age Gap in Rosacea Treatmenthttps://practicaldermatology.com/news/nrs-survey-reveals-age-gap-in-rosacea-treatment/2460553/Most rosacea patients are satisfied with the oral and topical prescription therapies they are using to treat this disorder, but individuals 60 and older are more likely to use older treatments, rather than newer products that may more effectively target specific signs and symptoms, finds a new Na
- Cynosure Launches FlexSure in US and Canadahttps://practicaldermatology.com/news/cynosure-launches-flexsure-device/2460552/Cynosure is launching FlexSure, the latest addition to the TempSure platform, in the US and Canada. FlexSure is a wrappable radiofrequency (RF) applicator for hands-free treatment on all patients and all skin types. With peel-and-sti
- With Label Extension, Simponi Aria Approved for PsA in Kids as Young as Twohttps://practicaldermatology.com/news/with-label-extension-simponi-aria-approved-for-psa-in-kids-as-young-as-two/2460549/The FDA has approved Simponi Aria (golimumab) for the treatment of active pJIA for patients two years of age and older and has extended the PsA indication for this same patient population. In Phase 3 clinical trials with pediatric patients, pharmacokinetic (PK) exposure of